» Articles » PMID: 24037576

Sarcopenia As a Predictor of Prognosis in Patients Following Hepatectomy for Hepatocellular Carcinoma

Overview
Journal Br J Surg
Specialty General Surgery
Date 2013 Sep 17
PMID 24037576
Citations 205
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sarcopenia was identified recently as a poor prognostic factor in patients with cancer. The present study investigated the effect of sarcopenia on short- and long-term outcomes following partial hepatectomy for hepatocellular carcinoma (HCC), and aimed to identify prognostic factors.

Methods: Data were collected retrospectively for all consecutive patients who underwent hepatectomy for HCC with curative intent between January 2004 and December 2009. Patients were assigned to one of two groups according to the presence or absence of sarcopenia, assessed by computed tomographic measurement of muscle mass at the level of the third lumbar vertebra. Clinicopathological, surgical outcome and long-term survival data were analysed.

Results: Sarcopenia was present in 75 (40·3 per cent) of 186 patients, and was significantly correlated with female sex, lower body mass index and liver dysfunction, as indicated by abnormal serum albumin levels and indocyanine green retention test at 15 min values. In patients with, and without sarcopenia, the 5-year overall survival rate was 71 and 83·7 per cent respectively, and the 5-year recurrence-free survival rate was 13 and 33·2 per cent respectively. Multivariable analysis revealed that reduced skeletal muscle mass was predictive of an unfavourable prognosis.

Conclusion: Sarcopenia was predictive of worse overall survival even when adjusted for other known predictors in patients with HCC after partial hepatectomy.

Citing Articles

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.

Eslam M, Fan J, Yu M, Wong V, Cua I, Liu C Hepatol Int. 2025; .

PMID: 40016576 DOI: 10.1007/s12072-024-10774-3.


Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma.

Wakamatsu R, Nakayama M, Wakamatsu A, Yamashita Y, Suto H, Katsuragawa M In Vivo. 2025; 39(2):988-999.

PMID: 40010999 PMC: 11884448. DOI: 10.21873/invivo.13904.


Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies.

Takamoto T, Mihara Y, Nishioka Y, Ichida A, Kawaguchi Y, Akamatsu N Int J Clin Oncol. 2025; 30(3):417-426.

PMID: 39907863 PMC: 11842484. DOI: 10.1007/s10147-025-02703-7.


Low skeletal muscle mass contributes to the prognosis of patients with superficial esophageal cancer treated with definitive chemoradiotherapy.

Nakagawa K, Hayashi Y, Adachi Y, Tajiri A, Fukuda H, Kimura E Esophagus. 2025; .

PMID: 39883331 DOI: 10.1007/s10388-025-01109-8.


CT-based skeletal muscle loss predicts long term prognosis in patients with distal cholangiocarcinoma undergone pancreaticoduodenectomy.

Qu G, Lyu S, Zhang Y, Gao K, Zhou C Sci Rep. 2025; 15(1):2885.

PMID: 39843804 PMC: 11754836. DOI: 10.1038/s41598-025-87458-x.